Bioanalysis of ibrutinib and its active metabolite in human plasma: selectivity issue, impact assessment and resolution

Bioanalysis. 2015;7(20):2713-24. doi: 10.4155/bio.15.159. Epub 2015 Oct 28.

Abstract

Ronald de Vries graduated in Organic and Analytical Chemistry at the Free University of Amsterdam, The Netherlands. After working in a Contract Laboratory (CRO) for 7 years, he joined Janssen R&D in 1998. At Janssen R&D, Belgium, Ronald worked in the bioanalytical department that supports both clinical and nonclinical bioanalysis. In this department he had several roles, such as providing the bioanalytical support for various drug development programs and leading the method establishment group. He has done numerous global assay transfers to/from Janssen from/to other laboratories and plays an important role in the introduction and application of new technologies and applied innovation in the department. In 2014 he started in the drug metabolism and pharmacokinetics department of Janssen R&D, where his main tasks are in vivo and in vitro metabolite identification using high resolution MS and Radiodetection.

MeSH terms

  • Adenine / analogs & derivatives
  • Agammaglobulinaemia Tyrosine Kinase
  • Bile Acids and Salts / chemistry
  • Blood Chemical Analysis / methods*
  • Blood Chemical Analysis / standards
  • Calibration
  • Chromatography, High Pressure Liquid / standards
  • Humans
  • Liver Diseases / metabolism
  • Liver Diseases / pathology
  • Piperidines
  • Protein-Tyrosine Kinases / antagonists & inhibitors
  • Protein-Tyrosine Kinases / metabolism
  • Pyrazoles / blood*
  • Pyrazoles / metabolism
  • Pyrimidines / blood*
  • Pyrimidines / metabolism
  • Quality Control
  • Tandem Mass Spectrometry / standards
  • Taurocholic Acid / chemistry

Substances

  • Bile Acids and Salts
  • Piperidines
  • Pyrazoles
  • Pyrimidines
  • ibrutinib
  • Taurocholic Acid
  • Protein-Tyrosine Kinases
  • Agammaglobulinaemia Tyrosine Kinase
  • Adenine